UNSPSC 51281639: Capreomycin ia

This classification denotes an antitubercular agent and aminoglycoside antibiotic with the molecular formula C25H44N14O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4AUQ151IUH, chemically known as cyclo(3-(((3s)-3,6-diamino-1-oxohexyl)amino)-l-alanyl-(2z)-3-((aminocarbonyl)amino)-2,3-didehydroalanyl-(2s)-2-((4r)-2-amino-1,4,5,6-tetrahydro-4-pyrimidinyl)glycyl-(2s)-2-amino-.beta.-alanyl-l-seryl), but more generally known as capreomycin ia, which bears US NIH Compound Identifier 3032940.

UNSPSC 51281639 Capreomycin ia is a Commodity code that maps poorly to state and local procurement activity in the recent record. The source shows no recent opportunities for capreomycin ia, a second-line tuberculosis antibiotic. Instead, the opportunities tagged to this code reflect pharmaceutical procurement of much broader scope — naloxone and drug deactivation systems, generic multi-source pharmaceuticals and OTC products, and direct-to-manufacturer prescription programs. These solicitations reveal that state and local health authorities are buying pharmaceuticals, medical supplies, and pharmacy benefit administration services, but the tagging to capreomycin ia does not reflect the actual commodities or services being procured. When code assignment diverges this sharply from the work actually being bought, the code signals little actionable activity for vendors focused on the narrowly defined product line.

The four opportunities in the recent record originate from diverse issuing bodies: Seminole County, Florida (naloxone and drug deactivation systems, IFB, response due July 26, 2023); Texas Health and Human Services Commission (pharmacy benefit direct-to-manufacturer program, RFI, response due April 3, 2026); City of Tampa (medical and first aid supplies for the Fire Department Rescue Division, IFB, response due March 13, 2026); and Minnesota Multistate Cooperative Purchasing Alliance administered by the Minnesota Department of Administration (generic multi-source pharmaceuticals and OTC products, RFP, response due March 26, 2026). The geographic footprint includes Florida, Texas, Minnesota, and Oregon (through the Minnesota cooperative), but the mismatch between code and commodity means that tracking activity under UNSPSC 51281639 does not reliably surface relevant state and local procurement for tuberculosis treatment supplies. Vendors pursuing opportunities in this space should identify and monitor pharmaceutical and health-supply solicitations directly through state health department RFPs and county health procurement portals rather than relying on this code's recent posting record.